Humana (HUM) Leerink Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Leerink Global Healthcare Conference 2026 summary
10 Mar, 2026Strategic priorities and margin outlook
Commitment to restoring Medicare margins to at least 3% and earnings power by 2028 remains unchanged, requiring benefit adjustments to match funding and medical cost trends.
Lifetime value of members is emphasized, with retention prioritized due to higher economic value in later years.
Medicare and CenterWell businesses must each be independently profitable, but together enhance overall economics and retention incentives.
Industry-wide benefit adjustments are expected in response to funding not keeping pace with medical cost trends, with a focus on minimizing member disruption.
Membership growth, mix, and retention
Over 1 million new members added during AEP, with about 70% being switchers, who are more economically favorable in year one than new-to-MA members.
70% of new members are in four-star or better contracts, and 75% come through higher-quality sales channels, reflecting deliberate actions to improve membership quality.
Sales channel optimization included trimming lower-performing call centers and broker partners to focus on retention and quality.
HMO/PPO mix remains consistent with previous years.
Margin profiles and product performance
Switchers have the highest margins, followed by returning members, with new-to-MA members having the lowest due to coding and acquisition costs.
D-SNP margins remain higher than non-D-SNP, with overall margin improvement expected across the membership due to rate notice, trend benders, and operational efficiency.
PPO products can be profitable if priced and structured appropriately, with recent years focused on correcting prior aggressive pricing.
Latest events from Humana
- Proxy covers director elections, executive pay, new stock plan, and ESG priorities.HUM
Proxy Filing6 Mar 2026 - Board recommends approval of all proposals except the golden parachute shareholder proposal.HUM
Proxy Filing6 Mar 2026 - Annual meeting covers director elections, compensation, new equity plan, and ESG progress.HUM
Proxy Filing6 Mar 2026 - FY 2025 adjusted EPS hit $17.14; 2026 guidance sees $9.00 EPS amid Stars headwinds.HUM
Q4 202511 Feb 2026 - Net income declined 29% as higher Medicare Advantage costs offset strong revenue growth.HUM
Q2 20242 Feb 2026 - Stabilized utilization, strategic plan exits, and conservative risk management support 2025 outlook.HUM
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Revenue and MA membership rose, but EPS fell as higher medical costs pressured margins.HUM
Q3 202417 Jan 2026 - 2024 adjusted EPS $16.21; 2025 guidance flat; Medicare Advantage to decline 10%.HUM
Q4 20248 Jan 2026 - Q1 2025 Adjusted EPS rose to $11.58, with FY 2025 guidance reaffirmed at $16.25.HUM
Q1 202527 Dec 2025